Association between anxiety and non-coding genetic variants of the galanin neuropeptide
Authors:
Gergely Keszler aff001; Zsuzsanna Molnár aff001; Zsolt Rónai aff001; Mária Sasvári-Székely aff001; Anna Székely aff002; Eszter Kótyuk aff002
Authors place of work:
Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary
aff001; MTA‐ELTE Lendület Adaptation Research Group, Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
aff002
Published in the journal:
PLoS ONE 14(12)
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0226228
Summary
Background
Galanin, an inhibitory neuropeptide and cotransmitter has long been known to co-localize with noradrenaline and serotonin in the central nervous system. Several human studies demonstrated altered galanin expression levels in major depressive disorder and anxiety. Pharmacological modulation of galanin signaling and transgenic strategies provide further proof for the involvement of the galanin system in the pathophysiology of mood disorders. Little is known, however, on the dynamic regulation of galanin expression at the transcriptional level. The aim of the present study was to seek genetic association of non-coding single nucleotide variations in the galanin gene with anxiety and depression.
Methods
Six single nucleotide polymorphisms (SNP) occurring either in the regulatory 5’ or 3’ flanking regions or within intronic sequences of the galanin gene have been genotyped with a high-throughput TaqMan OpenArray qPCR system in 526 healthy students (40% males). Depression and anxiety scores were obtained by filling in the Hospital Anxiety and Depression Scale (HADS) questionnaire. Data were analyzed by ANCOVA and Bonferroni correction was applied for multiple testing. Linkage disequilibrium (LD) analysis was used to map two haploblocks in the analyzed region.
Results and conclusions
A single-locus and a haplotype genetic association proved to be statistically significant. In single-marker analysis, the T allele of the rs1042577 SNP within the 3’ untranslated region of the galanin gene associated with greater levels of anxiety (HADS scores were 7.05±4.0 vs 6.15±.15; p = 0.000407). Haplotype analysis revealed an association of the rs948854 C_rs4432027_C allele combination with anxiety [F(1,1046) = 4.140, p = 0.042141, η2 = 0.004, power = 0.529]. Neither of these associations turned out to be gender-specific.
These promoter polymorphisms are supposed to participate in epigenetic regulation of galanin expression by creating potentially methylatable CpG dinucleotides. The functional importance of the rs1042577_T allele remains to be elucidated.
Keywords:
DNA methylation – Haplotypes – Molecular genetics – Alleles – emotions – anxiety – depression – Linkage disequilibrium
Introduction
Common affective disorders such as depression and anxiety emerge against the background of perturbed monoaminergic neurotransmission. Beyond the well-substantiated role of classical neurotransmitters such as norepinephrin and serotonin in the pathogenesis of mood disorders, a number of recent studies implicated coexpressed neuropeptides such as galanin, a 29 amino acid long inhibitory neurotransmitter and trophic factor [1], in anxiety and depression [2]. A Bayesian multivariate analysis of gene factors revealed that the galanin signaling system consisting of the stress-inducible galanin gene and three heptahelical galanin receptors seems to play a seminal role in the development of depression by enhancing the vulnerability to environmental stressors [3].
However, the exact function of galanin in depression still remains elusive. Data gained from animal studies suggest that galanin mediates depression-like behaviour [4], while other authors emphasize its antidepressant-like effects [5, 6].
Experimental data argue that the effects of galanin on anxiety are brain region specific and all three galanin receptors seem to mediate its anxiety-like effects. Intracerebroventricular administration of galanin resulted in anxiolytic-like action in rats [7], while its microinjection in rodent amygdala produced both anxiogenic [8] and anxiolytic effects [9]. The anxiolytic action was more predominant when galanin was infused into the dorsal raphe nucleus in rats [10]. However, intra-dorsal hippocampal administration of galanin induced anxiogenic-like behaviours that could be attenuated with a type 2 galanin receptor antagonist [11].
Importantly, these seemingly contradictory findings could be reconciled by showing that type 1 and type 2 galanin receptors mediate opposite anxiety-like effects in the rat dorsal raphe nucleus [12]. The anxiolytic action of the type 2 galanin receptor is underscored by the fact that Gal2R knockout mice exhibit an anxiogenic-like phenotype [13], while type 3 galanin receptor knockout animals display increased anxiety [14]. Polymorphisms in the gene encoding galanin receptor 2 seem to mediate the effect of environmental stressors and gene-environment interactions [15].
Differential expression of galanin has been implicated in a broad spectrum of neuropsychiatric disorders including post-traumatic stress disorder [16] and Lewy body disorder [17]. Human studies revealed a direct correlation between plasma galanin levels and the severity of major depressive disorder [18]. In contrast, intravenous administration of galanin to depressed individuals exerted fast antidepressant activity [19]. Moreover, profound alterations in mRNA expression and DNA methylation have been found in the galanin system in postmortem brain samples of patients with major depressive disorder [20].
Though the regulation of galanin expression is far from being fully characterized, some transcription factors [21], medicine [22] and exercise [22, 23] have been shown to upregulate galanin transcription. Several lines of compelling evidence suggest that non-coding DNA variations affecting important 5’ and 3’ regulatory as well as intronic sequences are associated with central nervous system disorders such as panic disorder [24], depression and anxiety [25–28] via altering transcription factor or microRNA binding sites.
As described above, other authors have already demonstrated associations between GAL polymorphisms and mood disorders, but no studies have been done to date to test this possible association in a non-clinical, largely normal, healthy sample. Thus, our goal was to figure out whether any genetic association is detectable between a set of marker SNPs representing the entire regulatory landscape of the galanin gene and mood characteristics in an ostensibly normal sample consisting of university students with no psychiatric history.
Materials and methods
Subjects
To test possible genetic associations between GAL polymorphisms and anxiety and depression, DNA samples from a previous study on anxiety were genotyped for GAL polymorphisms [29]. Thus, participants of the present investigation largely overlap with those of an earlier genetic association study where the associations of glial cell derived neurotrophic factor (GDNF) polymorphisms with mood characteristics were tested [29]. The non-related Caucasian (Hungarian) subjects who participated on a voluntary basis were students from several educational institutions from Budapest, Hungary. They gave written informed consent, provided buccal cell samples and filled out the Hospital Anxiety and Depression Scale (HADS) questionnaire. The study protocol was designed in accordance with guidelines of the Declaration of Helsinki, and was approved by the Scientific and Research Ethics Committee of the Medical Research Council (ETT TUKEB). Inclusion criteria were as follows: no past or present psychiatric history (based on self-report), age between 18–35 years, valid GDNF SNP genotypes and valid self-report data for the HADS scales.
A total of 597 independent subjects were genotyped with a high-throughput system, and filled out the HADS self-report questionnaire. Of them, 589 had no previous psychiatric history and 526 subjects were between 18–35 years. Therefore, we analyzed data from 526 participants (40.7% males, 59.3% females; mean age: 22.01 ± 3.1 years).
Phenotype characteristics
As described in our previous study on anxiety [29], participants completed the Hungarian version [30] of the Hospital Anxiety and Depression Scale [31]. The HADS questionnaire measures anxiety and depression on 7–7 items, scoring on a 0 to 3 Likert scale. It was originally developed to assess anxiety and depression in case of non-psychiatric hospital patients [31]. However, a great deal of studies have shown that it is an adequate tool to measure mood characteristics on non-clinical samples as well [32]. The Cronbach Alpha values of the HADS scales were adequate (Cronbach Alpha = 0.775 for the anxiety and 0.715 for the depression scale, respectively). The inter-correlation of the two scales was high (r = 0.561, p < 0.001). The sample’s mean scores were 6.55 (± 3.7) on the anxiety scale and 2.80 (± 2.7) on the depression scale.
SNP selection criteria
Single nucleotide polymorphisms (SNPs) were selected for genotyping from the Single Nucleotide Polymorphism database of NCBI (dbSNP) with a minor allele frequency greater than 0.05. The pairwise tagging method using r2 threshold of 0.8 by Haploview was used to determine tagging SNPs based on HapMap data to obtain a proper coverage of the GAL gene resulting in a mean distance of 1721 bp between the selected SNPs. Polymorphisms with a reference from previous association studies concerning neuropsychiatric disorders were preferred.
DNA preparation and SNP genotyping
Genomic DNA samples were isolated from buccal swabs as described previously [29]. Genotypes were determined applying the TaqMan® OpenArray™ Genotyping System (Thermo Fisher Scientific, Waltham, Massachusetts) that is based on sequence-specific, fluorescent TaqMan probes in combination with a high-throughput PCR system using nanoliter-scale sample volume and post-PCR (endpoint) detection. Genotyping panels were obtained from the manufacturer as immobilized target specific primers and fluorescent probes in a low density array format. Reaction mixtures containing approximately 100 ng DNA (range: 30–150 ng) and the 1× master mix (each deoxyribonucleoside triphosphate and the AmpliTaq Gold DNA-polymerase, provided by the manufacturer) were prepared on a 384-well sample plate and then loaded on the genotyping plates by the OpenArray™ Autoloader. PCR amplification was performed in the GeneAmp® PCR System 9700 (Thermo Fisher Scientific, Waltham, Massachusetts) following the manufacturer's instruction. Endpoint imaging of the allele specific FAM and VIC fluorescent intensities was made by the OpenArray™ NT Imager. Raw data were evaluated by the TaqMan Genotyper v1.2 software.
2% of the DNA samples were repeatedly applied on the OpenArray system, demonstrating a reproducibility exceeding 98%. In addition, a subsample was re-genotyped for two SNPs with a 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA) in triplicates for quality control.
Table 1 summarizes the main characteristics of six SNPs genotyped within the GAL gene. Genotype, chromosomal position, relative distances in the gene body and regional localisation for the tested GAL polymorphisms are presented for each SNP. Genotype frequencies, p values from the Hardy-Weinberg equilibrium (HWE) tests and call rate information are also presented. The rs694066 SNP exhibited an outstandingly small minor genotype frequency (0.8%), while the others vary between 6.5% and 13.1%. All genotypes were in Hardy-Weinberg equilibrium. Call rates exceeded 85% for each polymorphism.
Linkage disequilibrium analyses
Lewontin’s D’ as well as R2 values of linkage disequilibrium were determined using the HaploView 4.2 software [33]. Haplotypes were determined by the Phase programme [34–36]. Linkage disequilibrium values of the studied SNPs are displayed in Fig 1. Importantly, both Lewontin’s D’ and R2 analysis revealed two haplotype blocks. Haplotype block No. 1 encompasses rs948854, rs2097042, rs4432027 and rs694066 SNPs, while rs3136540 and rs1042577 belong to haplotype block No. 2.
Statistical analysis
Statistical analyses were carried out using SPSS 20.0 for Windows. Chi-square analysis was used to assess reliability of the measured genotype and allele frequencies. Lewontin’s D’ as well as R2 values of linkage disequilibrium were calculated using the HaploView 4.2 application [33]. Haplotypes were determined by the Phase program. To test gender differences, the Independent-Samples t-test was used. Correlation analyses were carried out to test the HADS scales relationship with age. One-way analyses of covariance (ANCOVA) was used to test genetic associations of the single and multiple marker analyses in an allele-wise design. Bonferroni correction for multiple testing was used to rule out false positive results [37]. The corrected level of significance was p < 0.00417, as the nominal p (threshold value 0.05) was divided by the number of analyses performed (6 SNPs x 2 HADS scales = 12). Two-way ANOVA was used for testing the effect of prior associations in males and females.
Results
Influence of age and gender on anxiety and depression scores
Testing for covariates included testing the relationships between age, gender and the measured phenotypes and genotypes. The HADS anxiety scale showed significant differences across males and females [t(524) = - 4.054; p<0.001]; namely, females showed a higher mean score (7.09) than males (5.78). The HADS depression scale did not differ across genders. For testing the relationship between age and the HADS scales, Pearson correlation was used. The anxiety scale significantly correlated with age (r = - 0.89, p = 0.042), while the depression scale showed no significant correlation. The genotype frequency differences in males and females were tested with Chi-square analyses and no significant differences were observed. The ANOVAs testing the genotype and age association did not show any significant association either. In summary, age and gender were used as covariates in all association analyses on account of their association with the phenotype.
Single-allele association analyses on mood characteristics with GAL polymorphisms
Table 2 summarizes the results obtained from the single-allele association analyses. Minor allele frequencies, anxiety and depression mean scores for the alleles of each tested SNPs are presented with the corresponding p values. Based on the one-way ANCOVAs, three nominally significant associations were found with the anxiety scale, and one with the depression scale. The results showed higher anxiety mean scores associated with the minor allele of rs948854 [F(1,136) = 3.865, p = 0.049572, η2 = 0.004, power = 0.502], rs4432027 [F(1,974) = 4.349, p = 0.037297, η2 = 0.004, power = 0.549] and rs1042577 [F(1,894) = 12.594, p = 0.000407, η2 = 0.014, power = 0.944]. The minor allele of rs1042577 associated with a higher mean score on the depression scale as well [F(1,894) = 5.718, p = 0.016996, η2 = 0.006, power = 0.666]. Bonferroni correction was applied to rule out possible false positive effects. After correcting for multiple testing, association of anxiety and rs1042577 remained significant. In the presence of the minor allele (T) of the rs1042577 the mean anxiety score was significantly higher (7.05±4.0) as compared to the major allele (G) carriers (6.15±3.5). The effect of this polymorphism explained 1.4% of the variability of anxiety. In this analysis, the covariate effect of gender but not that of age proved to be significant (p < 0.001).
Haplotype analyses
As a next step, haplotype analyses were performed involving the three SNPs significantly associated with anxiety comparing the combined effects of the risk alleles versus non-risk alleles. To this end, bipartite and tripartite haplotypes were set up by pairing the most significantly associated rs1042577 3’ UTR SNP with one or both of the less significantly associated 5’ SNPs as shown in Table 3. Upon comparing haplotype frequencies, it is striking that two major haplotypes are represented with outstanding frequency in each category. For example, in case of the rs1042577—rs948854 haplotypes the non-risk-allele combination (rs1042577 C—rs948854 T) and the one containing both risk alleles (rs1042577 T—rs948854 C) occurred most frequently (0.692 and 0.254, respectively, as compared to 0.040 and 0.014 of the C-C and T-T haplotypes). Similarly, in case of the tripartite haplotype a few combinations were very rare (e.g. rs1042577 C, rs948854 C, rs4432027 T: 0.001) or even unrepresented in the present sample (e.g. C–T–C or T–C- T). In case of all three analyses, the two major haploalleles made up about 95% of all haplotypes. The low frequency of some haplotypes is probably due to the high linkage between the SNPs (see Fig 1).
Thus, the haplotype analyses were carried out between the two most frequent haplotypes. One-way ANCOVAs were applied to both mood dimensions with the haploalleles of the significant SNPs from haploblock 1 (rs948854—rs4432027) and from both haploblocks (rs1042577—rs948854, rs1042577—rs4432027, rs1042577- rs948854—rs4432027). Age and gender were also included as covariates. As it can be seen in Table 4, the haplotype with the risk alleles of both 5’ UTR SNPs (rs948854_C—rs4432027_C) showed significantly higher anxiety mean score than the haplotype with non-risk alleles [F(1,1046) = 4.140, p = 0.042141, η2 = 0.004, power = 0.529]. Unexpectedly, however, any bi- or tripartite haplotype comprising the risk allele of the 3’ UTR SNP (rs1042577) which associated significantly with anxiety even after correcting for multiple testing, did not prove to be associated either with anxiety or depression.
Gender-specific effects
The HADS anxiety scores differed across the genders, and the covariate effect of gender was also significant in the analysis of rs1042577 and anxiety. Thus, we raised the question whether the effect of this single-locus SNP was gender-specific. To address this issue, a two-way ANOVA was carried out to test whether the effect of rs1042577 in the single-locus analyses differed between males and females. Results are presented in Fig 2. The analysis revealed a significant GAL rs1042577 main effect [F(1,893) = 11.571, p = 0.0007, η2 = 0.013, power = 0.925], and a significant gender main effect [F(1,893) = 21.253, p < 0.001, η2 = 0.023, power = 0.996]. However, their interaction was not significant. According to these results, the risk effect of the T allele of the GAL rs1042577 SNP for higher anxiety scores was present in both genders. Males with the T allele showed a mean anxiety score of 6.21 (±3.9) and the females’ mean anxiety score with this allele was 7.65 (±3.9) as compared to the 5.48 (±3.6) and 6.61 (±3.4) mean scores with the C allele in males and females. The significant gender main effect is in accordance with literary data [38], suggesting that females in general show higher anxiety scores than males.
Furthermore, we also tested whether the association between the rs948854—rs4432027 haplotype and anxiety is gender specific. The two-way ANOVA showed a significant rs948854—rs4432027 haplotype main effect [F(1, 1046) = 4.449, p = 0.035, η2 = 0.004, power = 0.559], a significant gender main effect [F(1,893) = 25.603, p < 0.001, η2 = 0.024, power = 0.999], but the interaction between the rs948854—rs4432027 haplotype and gender was not significant. According to the results (Fig 3), the risk haplotype group showed a higher mean anxiety score both in males (6.24 ± 4.2) and females (7.36 ± 3.9), as compared to the non-risk haplotype groups of males (5.57 ± 3.4) and females (6.98 ±3.5).
Discussion
Galanin has been shown to co-localize with and modulate the release of norepinephrine and serotonin, principal neurotransmitters in depression and anxiety. In contrast to former research aimed to find genetic associations between GAL gene variants and mood characteristics in subjects with clinical anxiety and depression [, the novelty of the present study is that it was performed on a cohort of apparently normal, healthy volunteers. Candidate single nucleotide polymorphisms were carefully selected to cover 5’ and 3’ regulatory as well as intronic sequences of the gene, and polymorphisms with previous association data were preferred. Genetic association analyses of six GAL single nucleotide polymorphisms with anxiety and depression have been carried out with one-way analyses of covariance in an allele-wise method. Allele frequencies calculated from our population corresponded very well to those available from the 1000 Genomes project. Four nominally significant single-locus associations have been observed in the present study. While GAL rs948854 and rs4432027 SNPs were found to associate with anxiety, the rs1042577 SNP was significantly associated with both anxiety and depression. The association between rs1042577 and anxiety remained significant following correction for multiple testing. The minor allele of this polymorphism is coupled with higher anxiety mean score (T) as compared to the major allele (C). This association was observable in both females and males.
Recent studies conducted on healthy samples also found that HADS anxiety and depression scores varied a lot among university students [39–41]. Importantly, our healthy sample was also quite stratified as 9.9% of the sample (n = 52) scored higher than 11 (mean score of 14.23 ± 2.278) and 11.4% of the sample (n = 60) scored lower than 3 (mean: 1.32 ± 0.673) on the anxiety scale. On the other hand, 9.7% of the sample (n = 51) scored higher than 6 (mean: 9.160 ± 1.902) and 11.6% scored 0 on the depression scale. These data imply that approximately 10% of our admittedly healthy sample had clinical anxiety and depression [32]. It is to note that the frequency of the rs1042577 risk T allele was significantly higher in the top 9.9% than in the bottom 11.4% anxiety groups (50.0% vs. 30.6%, p = 0.005, data not shown).
Haplotype analysis is a very effective tool to test possible allelic interactions. In the present study, comparing the risk allele of rs1042577 from haploblock 2 (see Fig 1) and the risk alleles of the other two SNPs from haploblock 1 (rs948854 and rs4432027) which showed nominally significant associations with anxiety did not yield any significant associations. However, significant association between haplotype rs948854 C_rs4432027_C and anxiety was observed suggesting a possible additive effect of the risk alleles in this haploblock.
The chromosomal distance between these SNPs is slightly more than 1 kb. Importantly, the C allele of each SNP is followed by a guanine nucleotide, creating CpG dinucleotides as potential DNA methylation sequences in the promoter [42]. One can therefore assume that their methylation might elicit anxiety via diminished galanin expression. High-resolution methylation mapping of the galanin promoter and functional studies are needed to clarify this assumption. Notably, the role of DNA methylation in the regulation of the galanin system was already suggested by Barde et al. [20].
To our best knowledge, this is the first study in the literature shedding light on the association of the rs1042577 single nucleotide variation with any phenotype. Though this polymorphism was analyzed in a study by Unschuld et al. [24], it was not found to be associated with panic disorder. Apart from psychiatric studies, Schäuble et al. [43] also tested this polymorphism, addressing the role of galanin in fat intake and early onset obesity but failed to find associations.
The rs1042577 SNP is localized to the 3’ untranslated region of the galanin gene, a sequence where miRNA binding sites are frequently found. In an attempt to ascribe a functional role to this polymorphism, we searched the online PolymiRTS Database 3.0 (http://compbio.uthsc.edu/miRSNP/) but it turned out that this polymorphism does not affect any known miRNA target sequences. It is also possible that this SNP affects mRNA stability or half-life by allele-specific recruitment of RNA binding proteins but this assumption lacks yet experimental evidence. The rs1042577 SNP is found within a weak CTCF binding site in the 3’UTR. This transcription factor plays multiple roles in transcriptional modulation and chromatin architecture [44]. The issue whether it really binds the 3’ UTR in the context of chromatin needs further investigation.
In summary, in this study we revealed two statistically significant associations between anxiety and the galanin rs948854_C–rs4432027_C haplotype and the rs1042577_T single-locus allele, respectively. These results should be corroborated using clinical samples and functional analyses should also be performed, addressing the role these sequence variants might play in governing galanin expression.
Zdroje
1. Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, Hökfelt T, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015;67(1):118–75. doi: 10.1124/pr.112.006536 25428932
2. Hökfelt T, Barde S, Xu ZD, Kuteeva E, Rüegg J, Le Maitre E, et al. Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness. Front Neural Circuits. 2018;12:106. doi: 10.3389/fncir.2018.00106 30627087
3. Juhasz G, Hullam G, Eszlari N, Gonda X, Antal P, Anderson IM, et al. Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci U S A. 2014;111(16):E1666–73. doi: 10.1073/pnas.1403649111 24706871
4. Kuteeva E, Hökfelt T, Wardi T, Ogren SO. Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci. 2008;65(12):1854–63. doi: 10.1007/s00018-008-8160-9 18500640
5. de Souza MM, Silote GP, Herbst LS, Funck VR, Joca SRL, Beijamini V. The antidepressant-like effect of galanin in the dorsal raphe nucleus of rats involves GAL2 receptors. Neurosci Lett. 2018;681:26–30. doi: 10.1016/j.neulet.2018.05.029 29787787
6. Lu X, Barr AM, Kinney JW, Sanna P, Conti B, Behrens MM, et al. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci U S A. 2005;102(3):874–9. doi: 10.1073/pnas.0408891102 15647369
7. Bing O, Möller C, Engel JA, Söderpalm B, Heilig M. Anxiolytic-like action of centrally administered galanin. Neurosci Lett. 1993;164(1–2): 17–20. doi: 10.1016/0304-3940(93)90846-d 7512244
8. Möller C, Sommer W, Thorsell A, Heilig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology. 1999;21(4):507–12. doi: 10.1016/S0893-133X(98)00102-X 10481834
9. Barrera G, Hernandez A, Poulin JF, Laforest S, Drolet G, Morilak DA. Galanin-mediated anxiolytic effect in rat central amygdala is not a result of corelease from noradrenergic terminals. Synapse. 2006;59(1):27–40. doi: 10.1002/syn.20208 16237681
10. Silote GP, Rosal AB, de Souza MM, Beijamini V. Infusion of galanin into the mid-caudal portion of the dorsal raphe nucleus has an anxiolytic effect on rats in the elevated T-maze. Behav Brain Res. 2013;252:312–7. doi: 10.1016/j.bbr.2013.06.023 23791934
11. Funck VR, Fracalossi MP, Vidigal APP, Beijamini V. Dorsal hippocampal galanin modulates anxiety-like behaviours in rats. Brain Res. 2018;1687:74–81. doi: 10.1016/j.brainres.2018.02.036 29499176
12. Morais JS, Souza MM, Campanha TM, Muller CJ, Bittencourt AS, Bortoli VC, et al. Galanin subtype 1 and subtype 2 receptors mediate opposite anxiety-like effects in the rat dorsal raphe nucleus. Behav Brain Res. 2016;314:125–33. doi: 10.1016/j.bbr.2016.08.007 27498247
13. Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav. 2007;86(1):8–20. doi: 10.1016/j.pbb.2006.11.024 17257664
14. Brunner SM, Farzi A, Locker F, Holub BS, Drexel M, Reichmann F, et al. GAL3 receptor KO mice exhibit an anxiety-like phenotype. Proc Natl Acad Sci U S A. 2014;111(19):7138–43. doi: 10.1073/pnas.1318066111 24782539
15. Gonda X, Hullam G, Antal P, Eszlari N, Petschner P, Hökfelt TG, et al. Significance of risk polymorphisms for depression depends on stress exposure. Sci Rep. 2018;8(1):3946. doi: 10.1038/s41598-018-22221-z 29500446
16. Barnabas K, Zhang L, Wang H, Kirouac G, Vrontakis M. Changes in galanin systems in a rat model of post-traumatic stress disorder (PTSD). PLoS One. 2016;11(12):e0167569. doi: 10.1371/journal.pone.0167569 27907151
17. Alexandris A, Liu AK, Chang RC, Pearce RK, Gentleman SM. Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders. Acta Neuropathol Commun. 2015;3:77. doi: 10.1186/s40478-015-0249-4 26621352
18. Wang YJ, Yang YT, Li H, Liu PZ, Wang CY, Xu ZQ. Plasma galanin is a biomarker for severity of major depressive disorder. Int J Psychiatry Med. 2014;48(2):109–19. doi: 10.2190/PM.48.2.d 25377152
19. Murck H, Held K, Ziegenbein M, Künzel H, Holsboer F, Steiger A. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology. 2004;29(9):1205–11. doi: 10.1016/j.psyneuen.2004.02.006 15219645
20. Barde S, Rüegg J, Prud'homme J, Ekström TJ, Palkovits M, Turecki G, et al. Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proc Natl Acad Sci U S A. 2016;113(52):E8472–E8481. doi: 10.1073/pnas.1617824113 27940914
21. Gresle MM, Butzkueven H, Perreau VM, Jonas A, Xiao J, Thiem S, et al. Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. Glia. 2015;63(6):1005–20. doi: 10.1002/glia.22798 25639936
22. Holmes PV, Yoo HS, Dishman RK. Voluntary exercise and clomipramine treatment elevate prepro-galanin mRNA levels in the locus coeruleus in rats. Neurosci Lett. 2006;408(1):1–4. doi: 10.1016/j.neulet.2006.04.057 16996684
23. Sciolino NR, Dishman RK, Holmes PV. Voluntary exercise offers anxiolytic potential and amplifies galanin gene expression in the locus coeruleus of the rat. Behav Brain Res. 2012;233(1):191–200. doi: 10.1016/j.bbr.2012.05.001 22580167
24. Unschuld PG, Ising M, Erhardt A, Lucae S, Kohli M, Kloiber S, et al. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J Affect Disord. 2008;105(1–3):177–84. doi: 10.1016/j.jad.2007.05.006 17573119
25. Davidson S, Lear M, Shanley L, Hing B, Baizan-Edge A, Herwig A, et al. Differential activity by polymorphic variants of a remote enhancer that supports galanin expression in the hypothalamus and amygdala: implications for obesity, depression and alcoholism. Neuropsychopharmacology. 2011;36(11):2211–21. doi: 10.1038/npp.2011.93 21716262
26. da Conceição Machado F, de Souza LV, Rangel M, Jara ZP, do Carmo Franco M. The antidepressant-like effect of galanin in the dorsal raphe nucleus of rats involves GAL2 receptors. Neurosci Lett. 2018;681:26–30. doi: 10.1016/j.neulet.2018.05.029 29787787
27. Unschuld PG, Ising M, Roeske D, Erhardt A, Specht M, Kloiber S, et al. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology. 2010;35(7):1583–92. doi: 10.1038/npp.2010.30 20237460
28. Wang YJ, Li H, Yang YT, Tie CL, Li F, Xu ZQ, et al. Association of galanin and major depressive disorder in the Chinese Han population. PLoS One. 2013;8(5):e64617. doi: 10.1371/journal.pone.0064617 23741354
29. Kotyuk E, Keszler G, Nemeth N, Ronai Z, Sasvari-Szekely M, Szekely A. Glial cell line-derived neurotrophic factor (GDNF) as a novel candidate gene of anxiety. PLoS One. 2013;8(12):e80613. doi: 10.1371/journal.pone.0080613 24324616
30. Muszbek K, Szekely A, Balogh EM, Molnár M, Rohánszky M, Ruzsa A, et al. Validation of the Hungarian translation of Hospital Anxiety and Depression Scale. Qual Life Res. 2006;15(4):761–6. doi: 10.1007/s11136-005-3627-8 16688508
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x 6880820
32. Caci H, Baylé FJ, Mattei V, Dossios C, Robert P, Boyer P. How does the Hospital and Anxiety and Depression Scale measure anxiety and depression in healthy subjects? Psychiatry Res. 2003;118(1):89–99. doi: 10.1016/s0165-1781(03)00044-1 12759165
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. doi: 10.1093/bioinformatics/bth457 15297300
34. Stephens MJ, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73(5):1162–9. doi: 10.1086/379378 14574645
35. Stephens MJ, Smith N, Donnelly P. Documentation for PHASE, version 2.0.2. 2003
36. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978–989. doi: 10.1086/319501 11254454
37. Miller R. G. Simultaneous statistical inference. 2nd ed, Springer-Verlag New York, 1981.
38. Feingold A. Gender differences in personality: a meta-analysis. Psychological Bulletin 1994;116(3):429–456. doi: 10.1037/0033-2909.116.3.429 7809307
39. Andrews B, Hejdenberg J, Wilding J. Student anxiety and depression: comparison of questionnaire and interview assessments. J Affect Disord. 2006 Oct;95(1–3):29–34. Epub 2006 Jun 9. doi: 10.1016/j.jad.2006.05.003 16764939
40. Kebede MA, Anbessie B, Ayano G. Prevalence and predictors of depression and anxiety among medical students in Addis Ababa, Ethiopia. Int J Ment Health Syst. 2019 May 6;13:30. doi: 10.1186/s13033-019-0287-6 31080499
41. Gan GG, Yuen Ling H. Anxiety, depression and quality of life of medical students in Malaysia. Med J Malaysia. 2019 Feb;74(1):57–61. 30846664
42. Kofler B, Evans HF, Liu ML, Falls V, Iismaa TP, Shine J, et al. Characterization of the 5'-flanking region of the human preprogalanin gene. DNA Cell Biol. 1995;14(4):321–9. doi: 10.1089/dna.1995.14.321 7536007
43. Schäuble N, Reichwald K, Grassl W, Bechstein H, Müller HC, Scherag A, et al. Human galanin (GAL) and galanin 1 receptor (GALR1) variations are not involved in fat intake and early onset obesity. J Nutr. 2005;135(6):1387–92. doi: 10.1093/jn/135.6.1387 15930442
44. Li J, Huang K, Hu G, Babarinde IA, Li Y, Dong X, et al. An alternative CTCF isoform antagonizes canonical CTCF occupancy and changes chromatin architecture to promote apoptosis. Nat Commun. 2019;10(1):1535. doi: 10.1038/s41467-019-08949-w 30948729
Článek vyšel v časopise
PLOS One
2019 Číslo 12
- Může hubnutí souviset s vyšším rizikem nádorových onemocnění?
- Polibek, který mi „vzal nohy“ aneb vzácný výskyt EBV u 70leté ženy – kazuistika
- AI může chirurgům poskytnout cenná data i zpětnou vazbu v reálném čase
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Antibiotika na nachlazení nezabírají! Jak můžeme zpomalit šíření rezistence?
Nejčtenější v tomto čísle
- Methylsulfonylmethane increases osteogenesis and regulates the mineralization of the matrix by transglutaminase 2 in SHED cells
- Oregano powder reduces Streptococcus and increases SCFA concentration in a mixed bacterial culture assay
- The characteristic of patulous eustachian tube patients diagnosed by the JOS diagnostic criteria
- Parametric CAD modeling for open source scientific hardware: Comparing OpenSCAD and FreeCAD Python scripts